On the other hand, Chang and coworkers showed that PI3K/Akt/mTOR signaling pathway inhibitors (BEZ235 or PI103), in combination with radiotherapy in resistant prostate cancer cell lines (PC-3RR, DU145RR and LNCaPRR), promote distribution of cell cycle toward (G2/M) phase and decrease of G0/G1 and S phases through reduced protein phosphorylation of p-CDK1, p-Chk1, p-Chk2, and p-Rb. Here, MTOR is linked to prostate carcinoma.